WO2000071078A3 - Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere - Google Patents

Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere Download PDF

Info

Publication number
WO2000071078A3
WO2000071078A3 PCT/FR2000/001422 FR0001422W WO0071078A3 WO 2000071078 A3 WO2000071078 A3 WO 2000071078A3 FR 0001422 W FR0001422 W FR 0001422W WO 0071078 A3 WO0071078 A3 WO 0071078A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammal
antitumoral
implementing
antiviral treatment
composition designed
Prior art date
Application number
PCT/FR2000/001422
Other languages
English (en)
Other versions
WO2000071078A2 (fr
Inventor
Philippe Erbs
Richard Jund
Original Assignee
Transgene
Philippe Erbs
Richard Jund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene, Philippe Erbs, Richard Jund filed Critical Transgene
Priority to EP00931350A priority Critical patent/EP1183371A2/fr
Priority to AU49314/00A priority patent/AU774391B2/en
Priority to JP2000619390A priority patent/JP2003500342A/ja
Priority to CA002374941A priority patent/CA2374941A1/fr
Publication of WO2000071078A2 publication Critical patent/WO2000071078A2/fr
Publication of WO2000071078A3 publication Critical patent/WO2000071078A3/fr
Priority to HK02106412.5A priority patent/HK1046426A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition destinée à la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifère comprenant: (i) une séquence d'acide nucléique codant pour tout ou partie du polypeptide p53, (ii) au moins une séquence d'acide nucléique codant pour tout ou partie d'un polypeptide ayant au moins une activité cytotoxique, lesdites séquences d'acide nucléique étant placées sous le contrôle des éléments nécessaires à leur expression dans une cellule hôte dudit mammifère.
PCT/FR2000/001422 1999-05-25 2000-05-25 Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere WO2000071078A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00931350A EP1183371A2 (fr) 1999-05-25 2000-05-25 Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
AU49314/00A AU774391B2 (en) 1999-05-25 2000-05-25 Composition designed for implementing an antitumoral or antiviral treatment in a mammal
JP2000619390A JP2003500342A (ja) 1999-05-25 2000-05-25 哺乳動物の抗腫瘍治療または抗ウイルス治療用に設計された組成物
CA002374941A CA2374941A1 (fr) 1999-05-25 2000-05-25 Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
HK02106412.5A HK1046426A1 (zh) 1999-05-25 2002-08-29 哺乳動物抗腫瘤和抗病毒治療的組合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/06892 1999-05-25
FR9906892A FR2794025A1 (fr) 1999-05-25 1999-05-25 Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere

Publications (2)

Publication Number Publication Date
WO2000071078A2 WO2000071078A2 (fr) 2000-11-30
WO2000071078A3 true WO2000071078A3 (fr) 2001-04-19

Family

ID=9546225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/001422 WO2000071078A2 (fr) 1999-05-25 2000-05-25 Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere

Country Status (7)

Country Link
EP (1) EP1183371A2 (fr)
JP (1) JP2003500342A (fr)
AU (1) AU774391B2 (fr)
CA (1) CA2374941A1 (fr)
FR (1) FR2794025A1 (fr)
HK (1) HK1046426A1 (fr)
WO (1) WO2000071078A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1327688A1 (fr) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses avec capacité lytique augmentée
WO2003093303A1 (fr) 2002-05-06 2003-11-13 Board Of Regents, The University Of Texas System Ciblage de proteines pour l'apport de reactifs therapeutiques ou de diagnostic
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US8470591B2 (en) * 2004-11-08 2013-06-25 Transgene S.A. Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
WO2015048312A1 (fr) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2016040892A1 (fr) 2014-09-13 2016-03-17 Novartis Ag Polythérapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016183A1 (fr) * 1994-11-17 1996-05-30 Cayla Genes suicide et associations d'analogues de nucleobases et nucleosides pyrimidiques avec des genes suicide en vue d'une therapie genique
US6030956A (en) * 1996-10-24 2000-02-29 Boulikas; Teni Combination gene therapy for human cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016183A1 (fr) * 1994-11-17 1996-05-30 Cayla Genes suicide et associations d'analogues de nucleobases et nucleosides pyrimidiques avec des genes suicide en vue d'une therapie genique
US6030956A (en) * 1996-10-24 2000-02-29 Boulikas; Teni Combination gene therapy for human cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 1998 (1998-02-01), XU M ET AL: "Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo.", XP002133391, Database accession no. PREV199800259754 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1998 (1998-10-01), EHINGER MATS ET AL: "p53-dependent and -independent differentiation of leukemic U-937 cells: Relationship to cell cycle control.", XP002133392, Database accession no. PREV199800491381 *
EXPERIMENTAL HEMATOLOGY (CHARLOTTESVILLE) OCT., 1998, vol. 26, no. 11, October 1998 (1998-10-01), pages 1043 - 1052, ISSN: 0301-472X *
MOLECULAR GENETICS AND METABOLISM FEB., 1998, vol. 63, no. 2, February 1998 (1998-02-01), pages 103 - 109, ISSN: 1096-7192 *
YANG B ET AL: "Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells.", CLINICAL CANCER RESEARCH, (1996 OCT) 2 (10) 1649-57., XP002133390 *

Also Published As

Publication number Publication date
HK1046426A1 (zh) 2003-01-10
AU774391B2 (en) 2004-06-24
FR2794025A1 (fr) 2000-12-01
EP1183371A2 (fr) 2002-03-06
AU4931400A (en) 2000-12-12
WO2000071078A2 (fr) 2000-11-30
CA2374941A1 (fr) 2000-11-30
JP2003500342A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
AU3907889A (en) Dna sequences encoding polypeptides having beta-1, 3-glucanase activity
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053455A3 (fr) Nouveaux acides nucleiques et polypeptides associes
HK1022701A1 (en) Exendin analogues, processes for their preparationand medicaments containing them exendin.
HK1026229A1 (en) Modified dorsal tissue affecting factor and compositions
EP0919622A3 (fr) Expression en surface d'une enzyme dans la thérapie génique à base de promédicaments
WO2000071078A3 (fr) Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
WO1994005791A3 (fr) Facteur influant sur la croissance du tissu dorsal et compositions
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
CA2281206A1 (fr) Genes de geranyl diphosphate synthase
WO2001049721A3 (fr) Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations
AU6028898A (en) Methods for cultivating cells and propagating viruses
WO2000074629A3 (fr) Composition destinee a la mise en oeuvre d'un traitement cytotoxique, notamment antitumoral ou antiviral, chez un mammifere
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
CA2253006A1 (fr) Gene hydroxylase de beta-carotene
AU1814995A (en) Galanin receptor, nucleic acids, transformed cells and uses thereof
EP1010761A4 (fr) Gene
WO2001053453A3 (fr) Nouveaux acides nucleiques de moelle osseuse et polypeptides associes
EP0763205A4 (fr) Sequences d'acides nucleiques regulant l'expression de genes specifiques aux poumons
EP0970192A4 (fr) ACIDE NUCLEIQUE CODANT UNE PROTEINE ALGU $i(M. TUBERCULOSIS)
WO1999031229A3 (fr) Peptides et acides nucleiques derives d'eisenia foetida et leur utilisation
ZA988570B (en) Nucleic acids, recombinant cells and a process for preparing immunogenic compositions.
WO2000070036A3 (fr) Molecules exprimees dans l'hippocampe

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 49314/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2374941

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 619390

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2374941

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000931350

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09979210

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000931350

Country of ref document: EP